Liver Disease
From the Journals
AGA Clinical Practice Update: Statins are safe, effective, and important for most patients with liver disease and dyslipidemia
With a few exceptions, patients with liver disease should receive lipid-lowering agents at full dose.
Conference Coverage
Primary cirrhotic prophylaxis of bacterial peritonitis falls short
A review of prospective data from 308 cirrhotic patients on antibiotic prophylaxis highlights the limitations of this treatment.
From the Journals
Neuropilin-1 surpasses AFP as HCC diagnostic marker
Neuropilin-1 was a more sensitive and specific marker for HCC than alpha fetoprotein, the current standard.
From the Journals
HCV remodels lipid metabolism in infected cells
From the Journals
Cigarette smoking epidemic among HCV-infected individuals
From the Journals
HCV and alcohol use disorder – bad news for the liver
From the Journals
Insurer denials of DAA therapy for HCV on the rise
About one in three patients had lack of fill approval by insurers.
From the Journals
Bezafibrate shows promise as second-line option for PBC
Approximately one-third of those who took bezafibrate had normal biomarkers after 24 months
From the Journals
Liver enzyme a marker of disease progression in primary biliary cholangitis
The liver enzyme autotaxin may be a useful noninvasive marker of disease progression in people with primary biliary cholangitis, new research has...
Video
VIDEO: Hepatitis C eradication cuts nonliver cancer rate
WASHINGTON - U.S. data from thousands of treated hepatitis C patients implicates the virus as carcinogenic and a factor in a wide range of...